Characterization of miRNA-regulated networks, hubs of signaling, and biomarkers in obstruction-induced bladder dysfunction

Ali Hashemi Gheinani,1 Bernhard Kiss,2 Felix Moltzahn,2 Irene Keller,1 Rémy Bruggmann,3 Hubert Rehrauer,4 Catharine Aquino Fournier,4 Fiona C. Burkhard,2 and Katia Monastyrskaya1,2

1Urology Research Laboratory, Department of Clinical Research, University of Bern, Bern, Switzerland. 2Department of Urology, University Hospital, Bern, Switzerland. 3Interfaculty Bioinformatics Unit, University of Bern, Bern, Switzerland. 4Functional Genomics Center Zurich, Zurich, Switzerland.

**Introduction**

Bladder outlet obstruction (BOO) induces significant organ remodeling, leading to lower urinary tract symptoms accompanied by urodynamic changes in bladder function. Here, we report mRNA and miRNA transcriptome sequencing of bladder samples from human patients with different urologically defined states of BOO. Patients’ miRNA and mRNA expression profiles correlated with urodynamic findings. Validation of RNA sequencing results in an independent patient cohort identified combinations of 3 mRNAs (NRXN3, BMP7, UPK1A) and 3 miRNAs (miR-103a-3p, miR-10a-5p, miR-199a-3p) sufficient to discriminate between bladder functional states. All BOO patients shared cytokine and immune response pathways, TGF-β and NO signaling pathways, and hypertrophic PI3K/AKT signaling pathways. AP-1 and NFkB were dominant transcription factors, and TNF-α was the top upstream regulator. Integrated miRNA-mRNA expression analysis identified pathways and molecules targeted by differentially expressed miRNAs. Molecular changes in BOO suggest an increasing involvement of miRNAs in the control of bladder function from the overactive to underactive/acontractile states.

In order to investigate the regulatory role of miRNAs in BOO-induced lower urinary tract dysfunction (LUTD), we performed an integrated analysis of miRNA and mRNA paired expression profiling in the bladder biopsies of human patients using comprehensive next-generation sequencing-derived (NGS-de-
rived) transcriptome data. We studied the activated pathways and altered biological processes based on the global gene expression changes and subsequently explored the presence and regulatory role of the individual miRNA targets in these pathways. We identified common and unique miRNAs and their mRNA targets characteristic of BOO-induced LUTD and specific for urodraulically defined states of the disease. Our approach allows systematic examination of the association between bladder function and the underlying activated biological processes (pathways and networks). We validated NGS-based findings in independent patient groups using quantitative PCR (QPCR) and present a rationale for biomarker selection, based on a combination of group-specific mRNA and miRNA markers. Using this tool allows discrimination among urodraulically defined BOO states, opening up diagnostic applications.

Results

Patient grouping after urodynamic assessment. Patients were recruited and examined as described in Methods. Group 1 patients, designated as “controls,” were mostly patients being treated for bladder stones with normal bladder function. In all patients with LUTS due to BOO (groups 2–4), urodynamic studies were performed, and the representative urodynamic evaluation is shown in Supplemental Figure 1 (supplemental material available online with this article; doi:10.1172/jci.insight.89560DS1), and full data are included in Supplemental Table 1. Based on questionnaires and urodynamic examination, the patients were divided into the following groups: group 2, which consisted of BOO with DO patients (referred to as DO patients); group 3, which consisted of BOO without DO patients (referred to as BO patients); and group 4, which consisted of patients with BOO with UA or acontractile bladders (referred to as UA patients below). The DO group included patients with increased detrusor pressure and reduced urine flow in combination with involuntary detrusor contractions during the filling phase (phasic and/or terminal). The BO group contained obstructed patients without involuntary detrusor contractions. The UA group consisted of patients with weak detrusor contractions (UA) or patients with acontractile detrusor and cystoscopy in line with obstruction. In all groups, 4 urothelium-covered muscle-containing biopsies were collected from the bladder dome by the same urologist and total RNA was isolated as described previously (12).

Overview of data analysis. The data analysis procedure is illustrated in Figure 1. Following the patient recruitment, urodynamic examination, and biopsy collection (step 1), mRNA and miRNA sequencing from the same RNA sample was performed (step 2) (n = 6 samples per group in control, DO, BO, and UA or n = 6 samples in control and n = 18 samples in the BOO group [DO, BO, and UA patients together], for a total of n = 24 samples). We used edgeR, and the group size was determined in accordance with Schurch et al. (17). Differentially expressed mRNAs and miRNAs were identified (step 3). mRNAs were used directly as an input for pathway analysis to generate pathways based on mRNA data set (step 7). The regulatory effect of differentially expressed miRNAs on the gene expression changes was evaluated by identifying the important hubs of intracellular signaling that they target. Abundant miRNAs (more than 500 reads), which are most likely to have biological activity, were selected in each patient group for further target prediction and pathway analysis (step 4). For each abundant miRNA, a list containing all top score bioinformatically predicted targets was generated (“Global targets,” step 5). Global targets then were paired with lists of expressed and regulated mRNAs from mRNA sequencing (step 3) to select the mRNA targets with opposite regulation respective of their miRNAs. These transcripts, designated “expressed targets” (step 6), were used for pathway analysis (step 7), resulting in pathways based on expressed miRNA targets or miRNA-regulated pathways (step 7).

miRNA and mRNA expression profiles correlate with urodraulically defined bladder function in patient groups. Differentially expressed mRNAs and miRNAs were determined in each BOO group (absolute fold change ≥1.5 time, P < 0.05, and adjusted P < 0.15). The overall number of differentially expressed mRNAs increased from 288 transcripts in the DO group to 958 in the BO group and 4,549 in the UA group. All 18 BOO-induced LUTD patients, compared with the 6 controls, yielded 663 significant differentially expressed transcripts (Supplemental Tables 8–11). Of 1,906 sequenced miRNAs, over 500 miRNAs were expressed in patients’ biopsies and controls, and the number of miRNAs significantly altered (P < 0.04) in different BOO states varied from 94 in the DO group, 182 in the BO group, and 236 in the UA group; all BOO patients pooled showed 158 significantly regulated miRNAs (Supplemental Tables 12–15). Top 5 abundant significant miRNAs strongly regulated in the DO, BO, and UA groups and all BOO patients are listed in Tables 1 and 2. Hierarchical clustering of mRNAs and miRNA revealed high expression profile similarity between DO and controls, whereas BO clustered with
Figure 1. Overview of NGS data analysis. The schema shows the data used as original input, the analytic steps, and two sets of pathway lists, built using differentially expressed mRNAs or expressed and inversely correlated targets of regulated abundant miRNAs. BOO, all patients with bladder outlet obstruction; C, controls; DO, obstructed patients with detrusor overactivity; BO, obstructed patients without detrusor overactivity; UA, obstructed patients with underactive bladders.
### Table 1. Top 5 differentially expressed miRNAs in the DO, BO, and UA groups

<table>
<thead>
<tr>
<th>miRNA name</th>
<th>Average read number</th>
<th>Average log₂ fold change</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>DO</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>hsa-miR-132-3p</td>
<td>664.8</td>
<td>3.4</td>
</tr>
<tr>
<td>hsa-miR-335-5p</td>
<td>2081.3</td>
<td>2.6</td>
</tr>
<tr>
<td>hsa-miR-374a-5p</td>
<td>20615</td>
<td>2.9</td>
</tr>
<tr>
<td>hsa-miR-146b-5p</td>
<td>116,900</td>
<td>2.9</td>
</tr>
<tr>
<td>hsa-miR-486-3p</td>
<td>20,615</td>
<td>2.9</td>
</tr>
<tr>
<td><strong>BO</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>hsa-miR-146b-5p</td>
<td>4,538.7</td>
<td>2.9</td>
</tr>
<tr>
<td>hsa-miR-21-3p</td>
<td>2061</td>
<td>2.8</td>
</tr>
<tr>
<td>hsa-miR-486-5p</td>
<td>26,415.3</td>
<td>2.8</td>
</tr>
<tr>
<td>hsa-miR-146a-5p</td>
<td>2,130.8</td>
<td>2.8</td>
</tr>
<tr>
<td>hsa-miR-146a-5p</td>
<td>2,130.8</td>
<td>2.8</td>
</tr>
<tr>
<td><strong>UA</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>hsa-miR-146b-5p</td>
<td>4,538.7</td>
<td>2.8</td>
</tr>
<tr>
<td>hsa-miR-146a-5p</td>
<td>2,130.8</td>
<td>2.8</td>
</tr>
<tr>
<td>hsa-miR-21-3p</td>
<td>2061</td>
<td>2.8</td>
</tr>
<tr>
<td>hsa-miR-146a-5p</td>
<td>2,130.8</td>
<td>2.8</td>
</tr>
<tr>
<td>hsa-miR-146a-5p</td>
<td>2,130.8</td>
<td>2.8</td>
</tr>
</tbody>
</table>

Abundant (read number in controls >500) and highly regulated miRNAs are shown. Table is sorted based on log₂ fold change. BOO, all bladder outlet obstruction patients; C, controls (n = 6 patients per group).

Changes in miRNA and mRNA expression reflect similar biological processes. An independently performed sample clustering, using miRNAs encoding contractile proteins and proteins involved in Ca²⁺ signaling, hypertrophy, and fibrosis showed that profibrotic transcripts were increased and smooth muscle–specific miRNAs were decreased in BO and UA samples (Figure 3A). In accordance, miRNA sequencing data revealed an upregulation of miRNAs known to control hypertrophy and profibrotic processes in the same sample clusters; on the other hand, muscle-specific miRNAs were downregulated in BO and UA groups but increased in the DO group (Figure 3B). Bioinformatic prediction of potential targets of the differentially expressed miRNAs identified several contractile proteins and proteins involved in fibrotic organ remodeling (Supplemental Table 2).

Receiver-operating characteristic curve analysis. A receiver-operating characteristic (ROC) curve analysis was applied to assess the discriminative potential of differentially expressed miRNAs and mRNAs for BOO patient groups (Figure 4). We identified 3 miRNAs (NRXN3, BMP7, and UPK1A) (Figure 4A) and 3 miRNAs (miR-103a-3p, miR-10a-5p, and miR-199a-3p) (Figure 4B) characteristic of each patient group, representing a different functional state of the bladder. The areas under the curve and upper and lower bound (95% CI) are presented in Supplemental Table 3. Levels of these miRNAs and mRNAs were examined by QPCR in independent groups of BOO patients (49 samples for miRNAs and 28 samples for mRNAs). Box-and-whisker plots were generated for the response variables in the mRNA (Figure 4A) and miRNA (Figure 4B) QPCR data sets classified by groups. The QPCR results indicate that NRXN3 and miR-103a-3p are regulated specifically in DO UA (Figure 2, A and B). These findings were confirmed by further analysis: in order to quantify the similarity between clusterings, a tanglegram (Figure 2C) was built by comparing the clusters made from the mRNA data set and the miRNA data set. The entanglement score (scoring: 0–1, 0 for best) was calculated. Dendrograms of both mRNA and miRNA samples had very good similarity with an entanglement score of 0.05.

### Table 2. Top 5 differentially expressed miRNAs in all BOO patients

<table>
<thead>
<tr>
<th>miRNA name</th>
<th>Average read number</th>
<th>Average BOO log₂ fold change</th>
</tr>
</thead>
<tbody>
<tr>
<td>hsa-miR-1</td>
<td>3,726.7</td>
<td>-3.1</td>
</tr>
<tr>
<td>hsa-miR-146b-5p</td>
<td>4,709.3</td>
<td>2.6</td>
</tr>
<tr>
<td>hsa-miR-21-3p</td>
<td>2,081.3</td>
<td>2.2</td>
</tr>
<tr>
<td>hsa-miR-146a-5p</td>
<td>2,263.9</td>
<td>2.0</td>
</tr>
<tr>
<td>hsa-miR-486-5p</td>
<td>26,415.3</td>
<td>1.8</td>
</tr>
</tbody>
</table>

Abundant (read number in controls >500) and highly regulated miRNAs are shown. Table is sorted based on log, fold change. BOO, all bladder outlet obstruction patients; C, controls (n = 6 patients per group).
Figure 2. Differentially expressed mRNAs and miRNAs in BDO-induced LUTD patients. (A) Hierarchical clustering and heatmap of log₂ fold change of 2,634 significantly regulated mRNAs (y axis) in 24 patients (x axis). (B) Hierarchical clustering of 343 significantly regulated miRNAs (y axis) and 24 samples (x axis). Hierarchical clustering of mRNAs and miRNAs revealed high expression profile similarity between DO and controls, whereas BO is similar to UA. (C) miRNA-mRNA tanglegram. Unique nodes, with a combination of patients not present in the other tree, are highlighted with dashed lines. Entanglement has the score of 0.05, indicating a very high similarity between the dendrograms of both mRNA and miRNA samples. (D) Principal component analysis of mRNA and miRNA expression was done based on profiles of 10,064 mRNAs (top) and 343 miRNAs (bottom) for each
patients, BMP7 and miR-199a-3p are characteristic of UA patients, miR-10a-5p is specifically upregulated in the BO group, and UPK1A is shared between the BO and UA groups. Thus, with an exception of UPK1A, specificity of all selected biomarkers was confirmed in independent patient groups (n = 12).

**Validation of NGS data and defining 3-mRNA and 3-miRNA signatures of bladder states.** We carried out QPCR using miRNA and mRNA expression assays on n ≥ 12 samples per group of independent BOO-induced LUTD patient biopsies. Group-specific miRNAs and mRNAs were selected based on ROC analysis; we also included genes and miRNAs, which were altered in all BOO patients. The clustering of patients based on QPCR results for 11 mRNAs (Figure 5A) and 18 miRNAs (Figure 5B) was similar to the clustering of patients based on NGS data (Figure 2, A and B). Fold differences for 6 significant mRNAs (BMP7, FOSL1, MYC, NRXN3, SERPIN1, and UPK1A) (Figure 5C) and miRNAs (miR-10a-5p, miR-29c-3p, miR-103a-3p, miR-142-3p, miR-199a-3p, and miR-342-3p) (Figure 5D) are shown.

Log fold change values for NRXN3, BMP7, and UPK1A mRNAs and miR-103a-3p, hsa-miR10a-5p, and hsa-miR-199a-3p miRNAs in bladder tissues of 32 and 28 patients, respectively, with different states of BOO, are illustrated in 3D scatter plots (Figure 5, E and F). The coordinates of each sample correspond to the log fold changes of the 3 mRNA or miRNA markers, and the confidence ellipse represents an isosceles triangle of the Gaussian distribution and allows visualization of a 3D confidence interval. The 3-mRNA and 3-miRNA signatures were sufficient to discriminate the DO, BO, and UA groups from each other.

**Testing the mRNA and miRNA signatures of bladder dysfunction states in a blinded study.** The 3-mRNA and 3-miRNA signatures of urodynamically defined bladder states were tested in an independent blinded follow-up study encompassing 40 patient biopsies and 11 control biopsies. Investigators conducting RNA isolations and QPCR assays for NRXN3, BMP7, and UPK1A mRNAs and miR-103a-3p, hsa-miR10a-5p, and hsa-miR-199a-3p miRNAs were not aware of the patients’ urodynamic status. Clustering of the miRNA results (Figure 6B) was similar to mRNA results (Figure 6A), clearly separating controls from BOO patients. Normalized Ct values for 3-mRNA or 3-miRNA signatures of the samples with the known urodynamic status (Figure 5, E and F) were employed in machine-based learning algorithms described in the Methods to train the model. Using the Ct values for either mRNA or miRNA signatures of the blinded samples as an input, the model allocated them to 3 groups corresponding to the predicted bladder functional state: BOO7, 24, 31, 32, 37, 38, 39, 40, 6, 5, 21, 22 and 23 belonged to the DO group; BOO16, 14, 15, 9, 8, 33, and 34 belonged to the BO group, and the remaining samples (BOO28, 29, 30, 41, 42, 10, 11, 12, 13, 17, 18, 19, 20, 4, 3, 2, 1, 25, 26, 27) were from the UA group. On the heatmaps, the samples were colored according to the machine-based group allocation (DO in blue, BO in green, and UA in orange) (Figure 6, A and B). Note that samples predicted to belong to the same group often colcluster.

To visualize the results, the log fold change values for each marker were plotted into 3D scatter plots, with samples predicted to share a urodynamic state occupying a concise ellipsoid, with 75% confidence interval (Figure 6, C and D). The 3D coordinates were close to the coordinates of the DO, BO, and UA samples shown in Figure 5, E and F. Urodynamic parameters and bladder function (diagnosis) of the BOO patients from the blinded study are shown in Supplemental Table 4. Lifting the code revealed that all patients were accurately allocated study are shown in Supplemental Table 4. Lifting the code revealed that all patients were accurately allocated.

**Gene enrichment analysis and miRNA-mediated regulation of pathway elements in the DO, BO, and UA groups.**

Despite the small size of the DO, BO, and UA groups (n = 6 patients each), sample clustering based on the differentially expressed mRNAs and miRNAs was in good agreement with urodynamic characterization of the patients’ bladder function (Figure 2, A and B for NGS; Figure 5, A and B, for QPCR). In order to study biological processes leading to the functional differences, we performed gene enrichment analysis using mRNA and miRNA target expression data from each group. miRNAs, regulated and abundant in each group (Supplemental Tables 16–19), were selected, and their expressed targets (Supplemental Tables 20–23) used to build signaling pathways. Top 10 canonical pathways based on mRNA and expressed miRNA target data sets for each group are shown in Supplemental Table 6 (full list of pathways in Supplemental Tables 24–29). Pathway analysis information was further integrated using Word Cloud and the Biological Function Classification Database to identify top signaling molecules and biological functions in each patient group. In the DO group (Figure 7A), KRAS,
Figure 3. Regulation of mRNA and miRNA expression reflects similar biological processes. (A) Hierarchical clustering of log2 fold changes of mRNA (y axis) encoding muscle-specific proteins, growth factors, proteins involved in Ca2+ homeostasis, and regulators of hypertrophy and fibrosis in BOD patients: obstructed patients with detrusor overactivity (DO), obstructed patients without detrusor overactivity (BO), obstructed patients with underactive bladders (UA), and controls (C) (x axis). (B) Hierarchical clustering of selected muscle-specific miRNAs and miRNAs regulated during hypertrophy and fibrosis. Smooth muscle-specific miRNAs and miRNAs decreased in BO and UA, but increased in DO samples; profibrotic transcripts and miRNAs were increased in BO and UA biopsies.
JUN, GNAQ, PTGS2, PRKAR2A, and MYC were among most recurrent signaling molecules occurring in 40 pathways with \( Z \) score based on mRNA sequencing data. From 35 significant pathways built using expressed miRNA targets, only 2 had a defined \( Z \) score. The word cloud of frequent elements from all significant pathways of the miRNA target data set contains CCND1, GNA13, DUSP8, ITDA5, SOCS3, and PTGS2 and shows little overlap with mRNA-based pathway elements. Comparison of the biological functions of 40 DO mRNA data set pathways (Figure 7A, yellow radar graph) to 35 miRNA-regulated pathways (Figure 7A, red radar graph) revealed that miRNA-regulated pathways were assigned substantially fewer biological functions.
In the BO group (Figure 7B), the word clouds of top pathway elements from mRNA and expressed miRNA target data sets were similar, sharing important signaling molecules, including JUN, FOS, MAP3K14, and MYC. In mRNA-based pathways, NFKB2 and PIK3R5 were the most prevalent, with a frequency of over 50 times. Biological functions of 94 pathways altered in BO patients based on the mRNA data set (Figure 7B, gray radar graph) were similar to those of 45 miRNA-regulated pathways (Figure 7B, blue radar graph), indicative of increasing involvement of BO miRNAs in the regulation of biological functions.

In the UA group, top regulatory elements from mRNA-based and expressed miRNA target-based pathways were highly similar (Figure 7C). In mRNA and expressed miRNA target data sets top pathway elements were members of phosphoinositide-3-kinase family followed by RAS family proteins. NFKB family proteins, JUN and FOS, were important transcription factors. The biological functions of 171 mRNA-based pathways in the UA group (Figure 7C, dark brown radar graph) showed a substantial overlap with 143 miRNA-regulated pathways (Figure 7C, khaki graph).

miRNAs regulate expression of downstream signaling elements in the DO, BO, and UA groups. Upstream regulator analysis was performed to study interactions of top 30 pathway elements in mRNA-based and miRNA target-based pathways from each group of patients (Supplemental Figure 2). In the DO mRNA data set (Supplemental Figure 2A), KRAS was the top upstream regulator and JUN was the most interactive element (12 connections). In the BO and UA groups, TNF was top upstream regulator, reflecting the increasing involvement of immune response pathways in these patients, and JUN was the main downstream signaling molecule (Supplemental Figure 2, B and C). In all groups, miRNAs targeted downstream molecules. In DO mRNA targets, KLF was the best-connected signaling molecule, with 5 links (Supplemental Figure 2D). The top BO miRNA-regulated element was IL-1A (13 downstream connections) (Supplemental Figure 2E). Similarly, analysis of the upstream regulator network in miRNA pathways of UA patients identified KRAS, with 7 connections, as the most interactive element (Supplemental Figure 2F). In this group, SRC was the top upstream signaling element.

Gene enrichment analysis and identification of miRNA-controlled pathways in all patients with BOO-induced LUTD. For gene expression changes characteristic of all BOO patients, gene enrichment analysis was performed using 662 significantly regulated transcripts compared with controls. Similarly, 158 significantly changed miRNAs were identified (Supplemental Tables 12–15). From 20 abundant BOO miRNAs, IPA target prediction retrieved the data for 12 miRNAs, and the expression pairing analysis resulted in 179 expressed miRNA targets. Top 10 pathways built using BOO mRNA and expressed miRNA target data sets were summarized in Supplemental Table 7 (Supplemental Tables 24–29 for the full list).

In BOO patients, the top pathway elements from mRNA and expressed miRNA target data sets were similar (Figure 8A). NFKB2, JUN, NRAS, TNF, and MAP3K14 were top 5 molecules, with an occurrence of 47, 45, 38, 27, and 25 times in 81 altered mRNA-based pathways (P < 0.05; absolute Z score value of ≥1). NRAS, JUN, CCND1, PTGS2, and MMP13 were top 5 elements of miRNA-regulated pathways in the BOO group. Comparing the biological functions of mRNA-based pathways (Figure 8B, orange radar graph) with miRNA target-based pathways in BOO patients (Figure 8B, brown graph), it is noticeable that miRNA-controlled processes contributed to fewer biological functions.

Upstream regulator analysis in mRNA-based pathways of all BOO patients revealed that TNF was the top upstream regulator, directly interacting with all top 30 molecules, except RHO, PPRCB, and...
NRAS (Supplemental Figure 3A). IL-1A, JUN, IL-6, IL-1B, MYC, and CXCL1 were the main downstream molecules. All miRNA-controlled elements were downstream of TNF and IL-1A (Supplemental Figure 3B). In most of its interactions, JUN is an upstream regulator of other genes and thus can be considered the top miRNA-targeted element influencing gene expression in BOO patients. CCND1 and PTGS2, on the other hand, were downstream miRNA targets.

Figure 6. Testing the 3-mRNA and 3-miRNA bladder dysfunction signatures in a blinded study. (A) Analysis of NRXN3, BMP7, and UPK1A mRNA expression in BOO patients of unknown urodynamic status and controls. Hierarchical clustering and heatmap of normalized Ct values of 3 signature mRNAs (y axis) in 40 patients and 11 controls (x axis). (B) Analysis of hsa-miR-103a-3p, hsa-miR-10a-5p, and hsa-miR-199a-3p miRNA expression in BOO patients. Hierarchical clustering and heatmap of normalized Ct values of 3 candidate miRNAs (y axis) in 38 BOO patients and 11 controls (x axis). Clustering of the miRNA results was similar to mRNA results, clearly separating controls from BOO patients. Using machine-based learning algorithms, the samples were allocated to phenotypic groups, represented by box border colors: green for DO (BOO with detrusor overactivity), blue for BO (BOO without detrusor overactivity), and orange for UA (underactive bladders) phenotypes. (C) 3D scatter plots for 3 mRNA biomarkers. Log2 fold change values of NRXN3, BMP7, and UPK1A mRNAs in bladder biopsies of 40 patients with unknown BOO states are plotted. Concentration ellipsoids are drawn to show the 3 patients groups (DO in green, BO in blue, and UA in orange). (D) 3D scatter plots and point identification for 3 miRNA biomarkers. Log2 fold change values of hsa-miR-103a-3p, hsa-miR-10a-5p, and hsa-miR-199a-3p miRNAs in bladder biopsies of 40 patients of unknown states of BOO are plotted. Ellipsoids are colored in green for DO-, blue for BO-, and orange for UA-allocated patients.
Figure 7. Gene enrichment analysis and pathway elements targeted by miRNAs in the DO, BO, and UA groups. (A) DO group. The word clouds show pathway elements in the mRNA data set and in the miRNA target data set. The radar graphs for biological functions of 40 mRNA data set pathways (yellow) and 35 expressed miRNA target pathways (red) in DO patients. In this group, there is little overlap between shown signaling hubs and miRNA-regulated signaling hubs; in addition, the miRNA-regulated pathways are assigned noticeably fewer biological functions. (B) BO group. The word clouds show path-
way elements in the mRNA data set and in the expressed miRNA target data set. The biological functions of 95 mRNA data set pathways (violet) and 45 expressed miRNA target pathways (blue). Here, the top pathway elements from mRNA and expressed miRNA target data sets share important signaling molecules. Biological functions of 94 altered pathways are similar to those of 45 miRNA-regulated pathways, indicative of increasing involvement of BO miRNAs in the regulation of signaling. (C) UA group. The word clouds show pathway elements in the mRNA data set and the expressed miRNA target data set. The biological functions of 171 pathways based on the mRNA data set (brown) and 143 pathways based on the expressed miRNA target data set (khaki). The top regulatory elements from mRNA-based and expressed miRNA target-based pathways are highly similar in the UA group, and there is a considerable overlap in biological functions of mRNA-based and miRNA-regulated pathways.

**Key signaling pathways defining organ remodeling in BOO-induced LUTD.** To identify the key cell signaling events important for bladder organ remodeling during BOO, we carried out a Venn analysis of all significant and regulated pathways (mRNA data sets) present in the DO, BO, and UA groups and in all BOO patients (Figure 8C). The 22 intersecting pathways (Table 3) were significant \( (P < 0.05 \text{ in all groups}) \) and regulated (absolute \( Z \) score value of \( \geq 1 \)). The heatmap of pathways based on the \( Z \) score (Figure 8D) showed the similarity of pathway activation in the BO group versus all BOO patients. Predicted pathway activity was the highest in the UA group, reflecting the biggest number of regulated miRNAs available for pathway analysis. Analysis of biological functions of the 22 common pathways (Figure 8E, radar graph) revealed that cellular growth, proliferation and development, and cytokine signaling were the main biological functions shared by all groups. The most frequent pathway elements identified in the 22 common pathways included NRAS, NFKB2, JUN, PRKCB, TNF, and MAP3K14 (Figure 8E, word cloud). Upstream analysis of transcription factors and cytokines in the 22 common pathways (Figure 8F) showed TNF, connected to 63 downstream elements, as the top upstream regulator.

**Impact assessment of abundant miRNAs and identification of disease-relevant miRNA targets.** We compared the number of abundant miRNAs altered in each condition (Figure 9A) to the number of significant pathways with a \( Z \) score that were built using expressed targets of these miRNAs (Figure 9B). The number of abundant miRNAs progressively increased among BOO states (9 miRNAs for DO, 23 miRNAs for BO, and 30 miRNAs for UA), in line with an increase of regulated transcripts identified by NGS in each group. Nevertheless, the number of miRNA-regulated pathways in each condition did not increase proportionally to the input of expressed miRNA targets used to build them. In the DO group, 109 miRNA targets of 9 miRNAs produced only 2 significant pathways with a \( Z \) score. In the BO group, 350 expressed targets of 23 miRNAs yielded 45 such pathways and in the UA group, 2,122 expressed targets of 30 miRNAs resulted in 143 significant pathways with a \( Z \) score prediction. These differences indicate that regulated abundant miRNAs may target a progressively increasing number of pathway elements in DO, BO, and UA.

Next, we calculated the effect of the miRNAs that were differentially expressed in all BOO patients. They accounted for 7.76% of all mRNA reads (Figure 9C). The most abundant differentially expressed miRNAs were miR-22-3p, miR-26b-5p, miR-21-5p, miR-181a-5p, and miR-191-5p (Figure 9C). Direct interaction of the 12 most abundant miRNAs with 66 mRNA targets represented among pathway elements of miRNA-regulated pathways is shown in Figure 9D. Downregulated miRNAs miR-497-5p, miR-26b-5p, and miR-29c-3p had 20, 17, and 17 inversely regulated mRNA targets among the pathway elements. Upregulated KLF, NRAS, and PTGS2 were targeted by 4, 3, 2 downregulated miRNAs (Figure 9D). Surprisingly, despite the high number of upregulated miRNAs, we identified very few of their targets among pathway elements. To address this discrepancy, we predicted targets of 36 regulated BOO miRNAs and analyzed their expression in the mRNA data set (Figure 1, step 6). From 19 upregulated and 17 downregulated BOO miRNAs, 221 and 215 mRNA targets, respectively, were present in the BOO mRNA data set. However, miRNA-mRNA expression pairing function revealed that only 25 targets (11%) of upregulated miRNAs were downregulated, whereas 194 targets (90%) of downregulated miRNAs were upregulated.

**Discussion**

During BOO, the increased outflow resistance induces hypertrophy, leading to organ failure due to advanced fibrosis and the subsequent loss of contractility. Here, we report quantitative transcriptome and miRNA profiling using biopsy samples from human patients with different states of urodynamically defined BOO-induced bladder dysfunction. Our results correspond well with those of previous studies in animal models of partial BOO (pBOO) and cardiac hypertrophy (19) and point to the similarity of mechanisms underlying organ remodeling during pressure overload.
miRNA and mRNA expression profiles in the BOO patients, assigned based on prior urodynamic examination into DO, BO, and UA groups, revealed a progressive increase in the number of altered miRNA and mRNAs from the DO group to the BO group to the UA group, with the most pronounced changes of miRNA and mRNA expression detected in the UA group. Both hierarchical and PCA demonstrated clustering of DO samples with controls and of BO samples with UA. The relative homogeneity of mRNA and miRNA expression profiles in UA samples could be explained by the lack of detrusor contractility in UA patients, which presents a more homogeneous functional phenotype. BO patients showed more variation in PCA plot, possibly due to the wide range of bladder contractility parameters within this patient group. Overall, the gene expression profiles correlated well with the functional characteristics of the bladder identified by urodynamics. The predictive performance of individual mRNAs and miRNAs for defining the functional state of the bladder was demonstrated by multivariate logistic regression analysis. Three-mRNA

Table 3. Key signaling pathways, defining organ remodeling in BOO-induced LUTD

<table>
<thead>
<tr>
<th>Pathways</th>
<th>DO</th>
<th>BO</th>
<th>UA</th>
<th>BOO vs. C</th>
</tr>
</thead>
<tbody>
<tr>
<td>-log(P value) Z score</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ERK5 signaling</td>
<td>2.99</td>
<td>2.449</td>
<td>2.64</td>
<td>1.877</td>
</tr>
<tr>
<td>PI3K/AKT signaling</td>
<td>2.75</td>
<td>1</td>
<td>1.58</td>
<td>0.447</td>
</tr>
<tr>
<td>Protein kinase A signaling</td>
<td>2.57</td>
<td>2</td>
<td>1.39</td>
<td>1.89</td>
</tr>
<tr>
<td>Colorectal cancer metastasis signaling</td>
<td>2.56</td>
<td>1.342</td>
<td>1.39</td>
<td>0.378</td>
</tr>
<tr>
<td>Cholecystokinin/gastrin-mediated signaling</td>
<td>2.29</td>
<td>2.236</td>
<td>2.19</td>
<td>1.897</td>
</tr>
<tr>
<td>TGF-β signaling</td>
<td>2.14</td>
<td>1.89</td>
<td>5.85</td>
<td>1.789</td>
</tr>
<tr>
<td>IGF-1 signaling</td>
<td>1.95</td>
<td>2.646</td>
<td>6.29</td>
<td>4.2</td>
</tr>
<tr>
<td>HGF signaling</td>
<td>1.84</td>
<td>1</td>
<td>1.91</td>
<td>2.828</td>
</tr>
<tr>
<td>STAT3 pathway</td>
<td>1.82</td>
<td>1</td>
<td>2.94</td>
<td>0</td>
</tr>
<tr>
<td>Pancreatic adenocarcinoma signaling</td>
<td>1.73</td>
<td>1.342</td>
<td>11.3</td>
<td>3.4</td>
</tr>
<tr>
<td>HMGB1 signaling</td>
<td>1.49</td>
<td>0</td>
<td>8.9</td>
<td>2.117</td>
</tr>
<tr>
<td>IL-1 signaling</td>
<td>1.45</td>
<td>2</td>
<td>6.2</td>
<td>-2.668</td>
</tr>
<tr>
<td>Endothelin-1 signaling</td>
<td>1.43</td>
<td>1.342</td>
<td>7.35</td>
<td>1</td>
</tr>
<tr>
<td>IL-8 signaling</td>
<td>1.43</td>
<td>1.342</td>
<td>7.35</td>
<td>1</td>
</tr>
<tr>
<td>Chemokine signaling</td>
<td>1.84</td>
<td>1</td>
<td>1.91</td>
<td>2.828</td>
</tr>
<tr>
<td>JAK/STAT signaling</td>
<td>1.82</td>
<td>1</td>
<td>2.94</td>
<td>0</td>
</tr>
<tr>
<td>Prolactin signaling</td>
<td>1.8</td>
<td>1</td>
<td>1.84</td>
<td>1.134</td>
</tr>
<tr>
<td>IL-6 signaling</td>
<td>1.73</td>
<td>1.342</td>
<td>11.3</td>
<td>3.4</td>
</tr>
<tr>
<td>Production of nitric oxide and reactive oxygen species in macrophages</td>
<td>1.49</td>
<td>0</td>
<td>8.9</td>
<td>2.117</td>
</tr>
<tr>
<td>PPAR signaling</td>
<td>1.45</td>
<td>-2</td>
<td>6.2</td>
<td>-2.668</td>
</tr>
<tr>
<td>ILK signaling</td>
<td>1.43</td>
<td>1.342</td>
<td>7.35</td>
<td>1</td>
</tr>
</tbody>
</table>

These pathways contain at least 3 of 4 of the most representative signaling molecules: JUN, NRAS, PTGS2, and NFKB2. BOO, all bladder outlet obstruction patients (n = 18 patients); DO, BOO patients with urodynamically determined detrusor overactivity; BO, BOO patients without detrusor overactivity; UA, underactive bladder; C, controls (n = 6 patients per group). LUTD, lower urinary tract dysfunction.
Figure 9. Regulatory role of miRNAs and their targets in different states of BOO. (A) Number of abundant miRNAs used for pathway analysis. miRNAs had at least 400 reads in control group and were significantly \( P < 0.05 \) regulated in their data set (\( \geq 1.5 \)-fold change). The number of abundant miRNAs progressively increased between BOO states: 9 for DO, 23 for BO, and 30 for UA. (B) Number of pathways built using miRNA targets. Pathways are significant \( (P < 0.05) \), with a Z score prediction. Regulated abundant miRNAs may target a progressively increasing number of pathway elements in DO, BO, and UA. (C) The abundances of individual miRNAs calculated as percentages of individual read counts in the BOO patient miRNA library. The relative content of the most abundant regulated miRNAs is shown. (D) Force-directed graph visualizing direct interaction of 12 miRNAs with 66 mRNA targets represented among pathway elements of miRNA-regulated pathways. Node color is indicative of direction of regulation, and node size is proportional to the absolute value of their log fold changes compared with controls. Downregulated miRNAs target the majority of important pathway elements in BOO. C, controls; DO, obstructed patients with detrusor overactivity; BO, obstructed patients without detrusor overactivity; UA, obstructed patients with underactive bladders.

(NRXN3, BMP7, and UPK1A) and three-miRNA (miR-103a-3p, miR-10a-5p, and miR-199a-3p) signatures were identified based on ROC curve analysis of NGS data and validated by QPCR in an independent patient population. A blinded follow-up study confirmed that these 3-mRNA and 3-miRNA signatures were sufficient to discriminate DO, BO, and UA groups.

Gene enrichment analysis in the DO mRNA data set showed that pathways characteristic for hypertrophy and cell differentiation were most important. Characteristic for the DO group was an activation of neurotransmitters and other nervous system signaling, including an upregulation of the DO-specific marker neurexin 3 (NRXN3). Comparative biological function analysis from the DO group to the BO group and the UA group indicated a progressive increase of the number of pathways, corresponding to immune response, growth responses, and apoptosis. Processes contributing to fibrosis and bladder cell dedifferentiation were enhanced, reflected by the downregulation of antifibrotic bone morphogenetic protein 7 (BMP7) and uroplakin genes, including UPK1A, specifically in UA and BO groups.

We identified 22 pathways shared by all BOO states. These included cytokine and immune response pathways, growth factor signaling pathways (TGF-β, HGF, and IGF-1), activation of GPCR pathways (endothelin and cholecystokinin/gastrin pathways), and NO signaling and hypertrophy-relevant PI3K/ AKT signaling pathways. The main transcription factors were activator protein AP-1 (JUN-FOS) and NFκB.

HMGB1 signaling was the most significant \(-\log(P\ value)=8.37\) shared activated pathway in all BOO patients, in line with its involvement in fibrotic disorders (20). Cytokine signaling, including IL-1, IL-6 and IL-8 signaling pathways, was highly activated during BOO. Endothelin and cholecystokinin/gastrin-mediated pathways in BOO mRNA data set are indicative of the role of GPCR signaling in bladder organ remodeling, similar to the changes observed in pressure overloaded heart (21). There is increasing experimental evidence of the involvement of endothelin in LUTS pathogenesis (22) and animal models of pBOO (23), supporting our data.

NFκB, involved in immune-related processes, and JUN were identified here as the key upregulated transcription factors during BOO. Our results are in line with animal and cell culture studies showing that BOO and stretch and growth factor stimulation upregulated NFκB and activator protein (AP-1) transcription factors (24). MYC, JUN, EGR1, MYB, and RUNX1 are the transcription factors important for fibroproliferative responses in smooth muscle cells (25).

PI3K/ AKT signaling was activated in BOO, and multiple genes encoding for constituents of this pathway are upregulated in BOO patients. This pathway has been shown to be highly regulated in cardiac hypertrophy (26). In particular, GPCR-coupled \( \beta_1 \) PI3K is prominent in heart pathology. TGF-β is a key player in wound healing, fibrosis, and negative regulation of inflammation, and its levels are increased in the majority of fibrotic diseases (27, 28). Here, we show that pathways involving TGF-β and modulator ERK5 (29) are considerably altered in all patient groups. Overall, within shared pathways, only PPAR signaling was predicted to be inhibited, in line with its antiinflammatory and antiproliferative effects (30).

Our study identified TNF-α as the top upstream regulator in all analyzed data sets (BOO and individual groups). These findings are supported by a previous study implicating this cytokine in developing bladder dysfunction in an animal model of type 2 diabetes, which is associated with bladder hypertrophy and overactivity (31). Similarly, studies using detrusor smooth muscle cells showed that TNF-α and IL-1β induced secretion of IL-8 and IL-6 (32), in line with our data in BOO patients. The source of TNF-α in the obstructed bladder was not investigated here, but a recent study in human bladder smooth muscle cells demonstrated that the inflammatory cytokines TGF-β (protein and mRNA), IL-1β, IL-6, and TNF-α (mRNA) were increased by hypoxia (33). Hypoxia is a hallmark of BOO (34), and our study demonstrated an increase of HIF1α mRNA levels in the patient biopsies, supporting this observation.

Here, we also delineated the miRNAs, common in all states of BOO-induced LUTD, as well as specific subsets of regulated miRNAs characteristic of each state. Several profibrotic miRNAs were upregulated in
BOO-induced LUTD, including miR-192 (35, 36) in the BO and UA groups and the hypoxia-induced miRNAs miR-34c (37) and miR-21 (38) in all groups. miR-146a-5p and miR-146b-5p were strongly upregulated in BOO patients. These findings were similar to those in the heart, where miR-146a-5p was elevated in diffuse miocardial fibrosis (39), while miR-146b-5p acted as a mediator in atrial fibrosis (40). Interestingly, miR-146b-5p is induced by angiotensin in cardiac fibroblasts (41). Angiotensin signaling plays an important role in DO in pBOO models (42) and might be an underlying cause of this miRNA upregulation in human patients. We identified the miR-212/132 cluster as upregulated in all BOO patient groups. These miRNAs control hypertrophy in the heart, and their synthesis is activated by calcineurin/NFAT signaling (43–45). The miR-212/132 cluster was upregulated in animals with pBOO (6), concomitant with activation of the calcineurin/NFAT pathway (46).

Notably, muscle-specific miRNAs, including miR-1, miR-133, and miR-143/145, were downregulated in BOO patients in parallel with a decrease in detrusor contractility. In pBOO animal models, miR-133 was downregulated during BOO-induced TGF-β-mediated hypertrophic and fibrotic responses (47). Similarly, miR-143 and miR-145, enriched in mature smooth muscle (48), were downregulated in the BO and UA groups.

When identifying the pathway elements appropriately regulated by differentially expressed miRNAs, it became apparent that the targets of upregulated miRNAs were disproportionately underrepresented. Only 11% of mRNA targets of upregulated miRNAs were inversely correlated and could be included in the analysis, in contrast to 90% of targets of the downregulated miRNAs. Our results are supported by the global transcriptome level studies showing that expression of only 10%–30% of mRNAs targeted by upregulated miRNAs was changed in the opposite direction (49, 50). Similar to our findings, most targets of the highly upregulated miR-21 and miR-34a in kidney cancer were increased at the mRNA and/or protein level (51). This phenomenon, which might be a manifestation of transcriptional override or a similar mechanism (52), awaits further investigation. Nevertheless, we paired 12 abundant differentially expressed miRNAs with mRNA targets involved in main activated pathways. Our data confirmed the role of miR-1 and miR-29c-3p previously identified in animal studies and implicated in pathogenesis of pBOO and bladder overactivity (53). We identified JUND, BDNF, and CCND1 among hubs of signaling activity targeted by miR-1 in human BOO patients. A recent expression profile in a rat pBOO model showed a decrease of miR-29b and miR-29c concomitant with an upregulation of c-Myc, NFkB, and SMAD3 (16). Our results confirm these findings in human patients with BOO. We paired miR-29c-3p with 17 mRNA targets participating in signaling pathways, including CREM, NRAS, KLF4, HEGF, and LIF. Interestingly, 3 of 7 abundant downregulated BOO miRNAs (miR-29c-3p, miR-26b-5p, and miR-497-5p) and several other shared miRNAs (miR-195-3p, miR-30c-5p, miR-195-3p, miR-100-5p, and let-7c-5p) from our study are repressed by activated Myc (54).

Our NGS and upstream regulator analysis identified Myc, activated in BOO-induced LUTD downstream of TNF-α, as one of the major hubs of signaling. TNF-α induces synthesis of miRNAs, including miR-155-5p and miR-146b-5p (55), which are upregulated in BOO patients. In line with downstream activation of NFkB, we detected downregulation of abundant miR-497-5p, which has been described as inhibited by NFkB (56). It targets SMAD3 (57), JUN, FOSL1, TNFSF9, CCND1, and other miRNAs involved in pathways altered in BOO patients. Similarly, upregulation of miR-486-5p, as detected here, is in line with activated TNF-α and NFkB signaling (58). These observations indicate that miRNAs might be involved in the secondary feedback loops rather than being primary drivers of the disease-mediated gene expression changes.

We did not examine the biopsies for cell composition and morphology, which is a limitation of this study. Previously, ultrastructural changes in the detrusor indicative of bladder hypertrophy and fibrosis were demonstrated by electron microscopy in human BOO patient biopsies (59, 60). However, the signs of inflammation and fibrosis did not correlate with the severity of BOO upon light microscopic examination (61). Therefore, a quantitative assessment of the mRNA and miRNA expression levels may be a more sensitive and reliable method for monitoring bladder remodeling when comparing BOO and control biopsies collected following the same procedure.

In summary, signaling pathways regulated in BOO-induced LUTD that we identified in this study show parallels with other conditions involving hypertrophy and fibrosis and support the animal models of bladder dysfunction. The number of miRNA-regulated pathways increased among the disease states from the DO group via the BO group to the UA group. Together with the upstream regulator analysis, these results suggest an increasing involvement of miRNAs in the control of bladder function from the overactive to underactive/contractile states. Relating the levels of circulating urinary miRNA, including the newly identified signature miRNAs, to the symptoms of BOO-induced dysfunction and inhibiting the fibrotic pathways described here in cell-based and animal models will lay foundation for the new diagnostic and therapeutic tools.
Methods

Data depository
The mRNA and miRNA sequencing data sets were deposited in the European Nucleotide Archive under accession numbers PRJEB11369 (for mRNAs) and ERP012260 (for miRNAs).

Patient selection, biopsy collection, and RNA isolation
Voiding symptoms were assessed in all patients by International Prostate Symptom Score (IPSS) and O’Leary-Sant questionnaires, pelvic pain VAS score, 48-hour urinary diary, and urinary free flow and sonographic measurements of residual urine volumes (62).

Group 1. Controls were mostly recruited from patients undergoing cystoscopy for stone treatment. They had IPSS score <8, O’Leary-Sant symptom index <6, O’Leary-Sant problem index <6, pelvic pain VAS score <4, voiding frequency <8/24 hours, a bell-shaped flow curve, and no post-void residual urine.

Groups 2–4 (BOO patents). In all patients with LUTS due to BOO, urodynamic studies were performed according to the International Continence Society (ICS) standards. Groups were defined according to ICS terminology after all urodynamic results had been reviewed by a second experienced functional urologist as follows.

Group 2 (DO patients). Group 2 patients had increased detrusor pressure and reduced urine flow during pressure flow in combination with involuntary detrusor contractions during filling phase (phasic and/or terminal), which was defined as obstructive according to the Abrams-Griffith nomogram.

Group 3 (BO patients). Group 3 patients were defined as obstructive according to the Abrams-Griffith nomogram and did not have involuntary detrusor contractions during filling phase.

Group 4 (UA patients). Group 4 patients were defined as having contractions of reduced strength and/or duration, resulting in prolonged bladder emptying and or failure to achieve complete bladder emptying within a normal time span (UA). Alternatively, these patients were found to be without detrusor contractions during urodynamic study (acontractile detrusor) and cystoscopy in line with obstruction.

miRNA and mRNA sequencing and pathway analysis
Illumina miRNA and mRNA sequencing. Both miRNA and mRNA sequencing were performed on the Illumina HiSeq 2000 using RNA isolated from the same patient’s biopsy. The TruSeq RNA Sample Prep Kit v2 (Illumina Inc.) was used for library preparation. The TruSeq PE Cluster Kit v3-cBot-HS or TruSeq SR Cluster Kit v3-cBot-HS (Illumina Inc.) was used for cluster generation using 10 pM of pooled normalized libraries on the cBOT. Sequencing was performed on the Illumina HiSeq 2000 (single-end 100 bp) using the TruSeq SBS Kit v3-HS (Illumina Inc.). For mRNA sequencing, read mapping to human reference genome hg19 was done using TopHat 2.0.9. Counting the number of reads per gene was done using HTSeq v0.5.4p3. The Bioconductor package edgeR (Bioconductor version release 3.2) was used to identify differentially expressed genes. For miRNA sequencing, input preprocessing, read mapping, read annotation, annotation analysis, and enrichment analysis were done via the ncPRO using the human genome build hg19 and mirBase v19. We used Bioconductor package Edge to identify differentially expressed miRNAs. We choose to set the threshold for FDR-adjusted P value to 0.15 in order to maximize the number of genes used to build the pathways.

miRNA target prediction. We used the miRNA Target Filter tool in IPA (QIAGEN; https://www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis/) to associate miRNAs from our miRNA sequencing data sets with experimentally observed and predicted mRNA targets. The predicted relationships are from TargetScan (v7.0; http://www.targetscan.org), and the experimentally observed relationships are from TarBase.

miRNA-mRNA expression pairing. We applied the miRNA-mRNA expression pairings function (IPA) to identify the direction of miRNA and mRNA expression changes. Then, we prioritized miRNAs and their targets by choosing those that were inversely correlated.

Prediction of biological function of canonical pathways. We built a tool in R program that searches for involvement of each IPA canonical pathway in the Biological Function Classification Database of IPA known as “Ingenuity canonical pathway” and counts the number of pathways involved in a specific biological function. The results are illustrated as radar graphs.

Z score calculation for activity of canonical pathways. In order to determine whether the activity of canonical pathways, including functional end points, is increased or decreased based on differentially expressed genes in the data sets, the pathway activity (Z score) was calculated by IPA.
Upstream regulator analysis. The upstream pathway analysis module of Ingenuity Pathway Analysis (IPA) (application build 377306M, dated March 26, 2016, content version 27216297 building_idris, dated March 16, 2016) was used to calculate upstream regulator enrichment. Overlapping P values were calculated by IPA using Fisher's exact test based on the significance of the overlap between the known targets and an experimentally identified set of regulated genes.

Hierarchical clustering and heatmaps. Hierarchical clustering and the associated heatmaps for miRNA and mRNA sequencing data were generated with the function heatmap2 in the R package gplots or Gene-E R package. The pairwise correlation matrix between items was computed (based on Pearson correlation method) and then converted as a distance matrix; finally, clustering was computed on the resulting distance matrix. The average linkage method used the average distance to calculate the distance matrix. For the heatmap visualization, the log2 expression values were used.

Visualizing and comparing trees of hierarchical clusterings. We used dendextend R package to create and compare visually appealing tree diagrams. Entanglement degree of two dendrograms was quantified by entanglement score. A lower entanglement coefficient corresponds to a good alignment. Entanglement was measured by matching the left and right trees as a vector, and entanglement equals the normal distance between vectors: score = Σ |x-y| / worst case entanglement level, where x represents the left tree label value, y represents the left tree label value, and L represents the penalty level that we assigned.

PCA. For a PCA of log2 fold change of mRNA and miRNA expression of BOO patients compared with controls, prcomp function implemented in R (R Core Team, 2016), rgl, and scatterplot3d R package were used for the PCA of 3D plots. To achieve better numerical accuracy, the calculation was performed using a singular value decomposition of the (centered and scaled) data matrix.

ROC curve analysis. ROC curve analysis was performed using SPSS (IBM Corp., released 2013, IBM SPSS Statistics for Windows, version 22.0.). We included the cutoff value for positive classification to see the power of miRNAs and mRNAs to differentiate the BOO patients. The area under the curve was calculated with 95% confidence interval. The area under the curve was accepted as significantly different from 0.5 when P value was greater than 0.5.

3D ellipsoid chart and point identification for biomarkers. The scatter3d() function in car (Companion to Applied Regression) package was used in order to call for the rgl package, which draws 3D scatter plots with various regression surfaces (http://cran.r-project.org) using XQuartz (The X Window System, version 2.7.9). In concentration ellipsoids, the DO patients are shown in green, BO group are shown in blue, and UA patients are shown in orange color. The data used to plot the graph were calculated based on calculation of distance of each value from the mean of the corresponding group. The coordination of each point on the 3D graph was identified shown in orange color. The data used to plot the graph were calculated based on calculation of distance of each value from the mean of the corresponding group. The coordination of each point on the 3D graph was identified by matching the left and right trees as a vector, and entanglement equals the normal distance between vectors: score = Σ |x-y| / worst case entanglement level, where x represents the left tree label value, y represents the left tree label value, and L represents the penalty level that we assigned.

Heatmap visualization, the log2 expression values were used.

PCA. For a PCA of log2 fold change of mRNA and miRNA expression of BOO patients compared with controls, prcomp function implemented in R (R Core Team, 2016), rgl, and scatterplot3d R package were used for the PCA of 3D plots. To achieve better numerical accuracy, the calculation was performed using a singular value decomposition of the (centered and scaled) data matrix.

ROC curve analysis. ROC curve analysis was performed using SPSS (IBM Corp., released 2013, IBM SPSS Statistics for Windows, version 22.0.). We included the cutoff value for positive classification to see the power of miRNAs and mRNAs to differentiate the BOO patients. The area under the curve was calculated with 95% confidence interval. The area under the curve was accepted as significantly different from 0.5 when P value was greater than 0.5.

3D ellipsoid chart and point identification for biomarkers. The scatter3d() function in car (Companion to Applied Regression) package was used in order to call for the rgl package, which draws 3D scatter plots with various regression surfaces (http://cran.r-project.org) using XQuartz (The X Window System, version 2.7.9). In concentration ellipsoids, the DO patients are shown in green, BO group are shown in blue, and UA patients are shown in orange color. The data used to plot the graph were calculated based on calculation of distance of each value from the mean of the corresponding group. The coordination of each point on the 3D graph was identified shown in orange color. The data used to plot the graph were calculated based on calculation of distance of each value from the mean of the corresponding group. The coordination of each point on the 3D graph was identified by matching the left and right trees as a vector, and entanglement equals the normal distance between vectors: score = Σ |x-y| / worst case entanglement level, where x represents the left tree label value, y represents the left tree label value, and L represents the penalty level that we assigned.

Heatmap visualization, the log2 expression values were used.

PCA. For a PCA of log2 fold change of mRNA and miRNA expression of BOO patients compared with controls, prcomp function implemented in R (R Core Team, 2016), rgl, and scatterplot3d R package were used for the PCA of 3D plots. To achieve better numerical accuracy, the calculation was performed using a singular value decomposition of the (centered and scaled) data matrix.

ROC curve analysis. ROC curve analysis was performed using SPSS (IBM Corp., released 2013, IBM SPSS Statistics for Windows, version 22.0.). We included the cutoff value for positive classification to see the power of miRNAs and mRNAs to differentiate the BOO patients. The area under the curve was calculated with 95% confidence interval. The area under the curve was accepted as significantly different from 0.5 when P value was greater than 0.5.

3D ellipsoid chart and point identification for biomarkers. The scatter3d() function in car (Companion to Applied Regression) package was used in order to call for the rgl package, which draws 3D scatter plots with various regression surfaces (http://cran.r-project.org) using XQuartz (The X Window System, version 2.7.9). In concentration ellipsoids, the DO patients are shown in green, BO group are shown in blue, and UA patients are shown in orange color. The data used to plot the graph were calculated based on calculation of distance of each value from the mean of the corresponding group. The coordination of each point on the 3D graph was identified shown in orange color. The data used to plot the graph were calculated based on calculation of distance of each value from the mean of the corresponding group. The coordination of each point on the 3D graph was identified by matching the left and right trees as a vector, and entanglement equals the normal distance between vectors: score = Σ |x-y| / worst case entanglement level, where x represents the left tree label value, y represents the left tree label value, and L represents the penalty level that we assigned.

Heatmap visualization, the log2 expression values were used.

PCA. For a PCA of log2 fold change of mRNA and miRNA expression of BOO patients compared with controls, prcomp function implemented in R (R Core Team, 2016), rgl, and scatterplot3d R package were used for the PCA of 3D plots. To achieve better numerical accuracy, the calculation was performed using a singular value decomposition of the (centered and scaled) data matrix.

ROC curve analysis. ROC curve analysis was performed using SPSS (IBM Corp., released 2013, IBM SPSS Statistics for Windows, version 22.0.). We included the cutoff value for positive classification to see the power of miRNAs and mRNAs to differentiate the BOO patients. The area under the curve was calculated with 95% confidence interval. The area under the curve was accepted as significantly different from 0.5 when P value was greater than 0.5.

3D ellipsoid chart and point identification for biomarkers. The scatter3d() function in car (Companion to Applied Regression) package was used in order to call for the rgl package, which draws 3D scatter plots with various regression surfaces (http://cran.r-project.org) using XQuartz (The X Window System, version 2.7.9). In concentration ellipsoids, the DO patients are shown in green, BO group are shown in blue, and UA patients are shown in orange color. The data used to plot the graph were calculated based on calculation of distance of each value from the mean of the corresponding group. The coordination of each point on the 3D graph was identified shown in orange color. The data used to plot the graph were calculated based on calculation of distance of each value from the mean of the corresponding group. The coordination of each point on the 3D graph was identified by matching the left and right trees as a vector, and entanglement equals the normal distance between vectors: score = Σ |x-y| / worst case entanglement level, where x represents the left tree label value, y represents the left tree label value, and L represents the penalty level that we assigned.

Heatmap visualization, the log2 expression values were used.

PCA. For a PCA of log2 fold change of mRNA and miRNA expression of BOO patients compared with controls, prcomp function implemented in R (R Core Team, 2016), rgl, and scatterplot3d R package were used for the PCA of 3D plots. To achieve better numerical accuracy, the calculation was performed using a singular value decomposition of the (centered and scaled) data matrix.

ROC curve analysis. ROC curve analysis was performed using SPSS (IBM Corp., released 2013, IBM SPSS Statistics for Windows, version 22.0.). We included the cutoff value for positive classification to see the power of miRNAs and mRNAs to differentiate the BOO patients. The area under the curve was calculated with 95% confidence interval. The area under the curve was accepted as significantly different from 0.5 when P value was greater than 0.5.

3D ellipsoid chart and point identification for biomarkers. The scatter3d() function in car (Companion to Applied Regression) package was used in order to call for the rgl package, which draws 3D scatter plots with various regression surfaces (http://cran.r-project.org) using XQuartz (The X Window System, version 2.7.9). In concentration ellipsoids, the DO patients are shown in green, BO group are shown in blue, and UA patients are shown in orange color. The data used to plot the graph were calculated based on calculation of distance of each value from the mean of the corresponding group. The coordination of each point on the 3D graph was identified shown in orange color. The data used to plot the graph were calculated based on calculation of distance of each value from the mean of the corresponding group. The coordination of each point on the 3D graph was identified by matching the left and right trees as a vector, and entanglement equals the normal distance between vectors: score = Σ |x-y| / worst case entanglement level, where x represents the left tree label value, y represents the left tree label value, and L represents the penalty level that we assigned.

Heatmap visualization, the log2 expression values were used.

PCA. For a PCA of log2 fold change of mRNA and miRNA expression of BOO patients compared with controls, prcomp function implemented in R (R Core Team, 2016), rgl, and scatterplot3d R package were used for the PCA of 3D plots. To achieve better numerical accuracy, the calculation was performed using a singular value decomposition of the (centered and scaled) data matrix.

ROC curve analysis. ROC curve analysis was performed using SPSS (IBM Corp., released 2013, IBM SPSS Statistics for Windows, version 22.0.). We included the cutoff value for positive classification to see the power of miRNAs and mRNAs to differentiate the BOO patients. The area under the curve was calculated with 95% confidence interval. The area under the curve was accepted as significantly different from 0.5 when P value was greater than 0.5.
by the investigators blinded to the urodynamic state of the patients. The samples belonged to the control group or patient (BOO) group, with no further details of the patients' bladder function provided. Expression levels of 3 miRNAs (hsa-miR-103a-3p, hsa-miR-10a-5p, and hsa-miR-199a-3p) and 3 mRNAs (NRXN3, BMP7, and UPCA1) were examined by QPCR, and the samples were allocated to the DO, BO, or UA group using machine-based learning algorithms. Plotting log, fold change values relative to controls into 3D scatter plots allowed for the visualization of the confidence interval of sample distribution. Following the blinded sample grouping and patient status decoding, the urodynamic data for each patient were revealed and the molecular signature-based results were correlated with the functional diagnosis.

Statistics

Hierarchical clustering and heatmaps. Hierarchical clustering and the associated heatmaps for miRNA and mRNA sequencing data were generated with the function heatmap2 in the R package gplots or Gene-E R package. Pairwise correlation matrices between items were computed based on the Pearson correlation method. The average linkage method used average to calculate the distance matrix. For the heatmap visualization, the log₂ expression values were used. We used dendextend R package to create and compare visually appealing tree diagrams.

PCA. Prcomp function implemented in R (R Core Team, 2016), rgl, and scatterplot3d R package were used for the PCA of 3D plots. The calculation was performed using a singular value decomposition of the (centered and scaled) data matrix.

ROC curve analysis. ROC curve analysis was performed using SPSS (IBM Corp., released 2013, IBM SPSS Statistics for Windows, version 22.0). The area under the curve was calculated with 95% confidence interval.

Z score calculation for activity of canonical pathways. Z score (IPA – Pathways) was used to mathematically compare the uploaded data set (differentially expressed mRNAs) with the canonical pathway patterns. The significance values for the canonical pathways were calculated by right-tailed Fisher's exact test.

Upstream regulator analysis. The upstream pathway analysis module of IPA (application build 377306M, dated March 26, 2016, content version 27216297 build ing_idris, dated March 16, 2016) was used. Overlapping P values were calculated by IPA using Fisher's exact test based on the significance of the overlap between the known targets and an experimentally identified set of regulated genes.

3D ellipsoid chart and point identification for biomarkers. The scatter3d() function in car (Companion to Applied Regression) package was used in order to call for rgl package, which draws 3D scatter plots with various regression surfaces (http://cran.r-project.org) using XQuartz (The X Window System, version 2.7.9). The coordination of each point on the 3D graph was identified based on its Mahalanobis distance from the centroid of the 3 variables.

QPCR validation of NGS studies. To choose reference (endogenous control) miRNA, expression stabilities of the different miRNAs were evaluated using NormFinder R package. Normalized values were centered and scaled. A 1-way ANOVA was employed, and the Tukey correction was used to correct P values. P < 0.05 was considered statistically significant (GraphPad Prism, version 6.0).

Classifiers identification (blinded test). Machine-learning algorithms (naive Bayes, support vector machine, random forests, and k-nearest neighbor) were used in this study to train and examine the power of biomarkers. The algorithms were trained with biomarker expression Ct values of the known samples, and subsequently Ct values of blinded samples were used as input for decoding.

Study approval

Approval to conduct this study was obtained from the ethics committee of Canton Bern, Switzerland (KEK 146/05 original study, KEK 331/14 follow-up blinded study), and all subjects gave written informed consent. The study is registered in ClinicalTrials.gov (Protocol Record 331/2014, ClinicalTrials.gov identifier: NCT01482676).

Author contributions

AHG, FCB, and KM designed the study; FCB supervised the patient recruitment; FCB, FM, and BK examined the patients and collected biopsies; AHG and KM performed the experiments; IK, RB, CAF, and HR conducted NGS; AHG analyzed the data; and AHG, FCB, and KM wrote the manuscript.
Acknowledgments

The authors thank Andrea Bucher for expert technical assistance. We are grateful to Rosalyn M. Adam (Department of Urology, Boston Children's Hospital, Boston, Massachusetts, USA) for many helpful discussions and critically reading the manuscript. We thank Janine Hensel for discussions and Ivonne Koeck for help in data validation. The financial support of the Swiss National Science Foundation (SNF grant 320030_156161/1) and the Velux Foundation (grant 895) is gratefully acknowledged.

Address correspondence to: Katia Monastyrskaya, Urology Research Laboratory, Department of Clinical Research, University of Bern, Bern, Switzerland. Phone: 41.31.632.87.19; E-mail: monastyk@dkf.unibe.ch. Or to: Fiona C. Burkhard, Department of Urology, Inselspital, University Hospital Bern, CH-3010 Bern, Switzerland. Phone: 41.31.632.2725; E-mail: fiona.burkhard@insel.ch.